TD Cowen raises target for Schrodinger stock to USD 31.00

Published on 10/20/2026 at 21:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 58.89 million in the quarter reported August 5. Schrodinger stock costs EUR 21.04 on October 20, 2026 at 9:04 p.m. CEST.

Analyst target and quarterly figures

TD Cowen raised its Schrodinger target from USD 20.00 to USD 31.00 on October 13, 2026.
Eight analysts had a Moderate Buy consensus with an average target of USD 23.50 on October 14, 2026.
Schrodinger stock traded at EUR 21.04 at Lang & Schwarz on October 20, 2026 at 9:04 p.m. CEST.
Quarterly revenue reached USD 58.89 million and increased 7.50 percent year over year.

SDGR, US80810D1037, Illustration mit AI erstellt.

TD Cowen analyst Brendan Smith raised the target for Schrodinger from USD 20.00 to USD 31.00 on October 13, 2026, while maintaining a Buy rating, Markets Insider reported. Schrodinger stock was trading at EUR 21.04 at Lang & Schwarz on October 20, 2026 at 9:04 p.m. CEST.

Target rises above recent consensus

The USD 31.00 target is 30.84 percent above the USD 23.67 Nasdaq price reported at 3:06 p.m. EDT on October 20, 2026. The calculation uses the same home-exchange currency for both values and places the TD Cowen view well above the latest market quote.

MarketBeat wrote on October 14, 2026 that eight analysts held a Moderate Buy consensus, with an average 12-month target of USD 23.50. The reported range ran from USD 19.00 to USD 32.00, leaving the TD Cowen target near the upper end of the group.

Stock remains below its yearly high

Schrodinger traded between a 52-week low of USD 10.95 and a 52-week high of USD 33.78 in the finance quote dated October 20, 2026. The USD 23.67 Nasdaq price stood USD 10.11 below the high and USD 12.72 above the low. Volume was 786,106 shares, while market capitalization was USD 1.8 billion.

Quarterly revenue and valuation

In quarterly results reported on August 5, 2026, revenue reached USD 58.89 million and increased 7.50 percent from the comparable period, according to MarketBeat. Reported earnings per share were USD 0.08, compared with a consensus loss of USD 0.41. The company develops computational software for pharmaceutical and materials research, alongside its drug-discovery programs.

The finance quote dated October 20, 2026 showed a negative price-to-earnings ratio of 31.94 and earnings per share of negative USD 0.74. Those figures describe a company whose valuation depends more on software growth, drug-development progress and future earnings potential than on current net income.

What the target means for valuation

The analyst target and the quarterly figures point to two separate tests for the stock. The first is whether commercial software revenue can sustain the 7.50 percent year-over-year increase. The second is whether drug-discovery development can support the higher expectations embedded in a USD 31.00 target. The market capitalization of USD 1.8 billion and the negative price-to-earnings ratio keep execution central to the valuation discussion.

Price and analyst view

Schrodinger was trading at EUR 21.04 at Lang & Schwarz on October 20, 2026 at 9:04 p.m. CEST. The Nasdaq quote was USD 23.67 at 3:06 p.m. EDT on the same date, while the 52-week high was USD 33.78.

The further course of trading is shown by the continuously updated real-time quote of Schrodinger stock.